Skip to main content

Apogee Therapeutics, Inc.

APGEDelisted
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001974640

Apogee Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Apogee Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $4.14M in total
Insiders trading
2
Net value
−$4.14M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Apogee Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Apogee Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Harwin Peter EvanDirector0IndirectSep 3, 20263
Fairmount Healthcare Fund II L.P.Director0IndirectSep 3, 20263
Fairmount Funds Management LLCDirector0IndirectSep 3, 20264
Kiselak TomasDirector0IndirectSep 3, 20264
McKenna Mark C.Director0Sep 3, 20262
Jones William A JrDirector0Sep 3, 20262
Dambkowski CarlChief Medical Officer0Sep 3, 202615
Fox Jennifer A.Director0Sep 3, 20262
Henderson JaneChief Financial Officer0Sep 3, 202614
Bollinger LisaDirector–Sep 3, 20262
Henderson Michael ThomasChief Executive Officer0Sep 3, 202614
Shah Nimish PDirector0IndirectSep 3, 20263
Gottesdiener AndrewDirector–Jun 20, 20250
Fairmount Healthcare Fund L.P.Director2,048,647IndirectApr 1, 20240
Fairmount Healthcare Co-Invest II L.P.Director51,166IndirectJan 31, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 7, 2026 (view filing)8:00 PM ETAug 52 daysDambkowski CarlChief Medical OfficerSSale−5.50K$134.17−$737.9K−3.2%168.5K after10b5-1
Jul 10, 2026 (view filing)8:00 PM ETJul 82 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$133.63−$2.67M−2.0%996.0K after10b5-1
Jul 2, 2026 (view filing)8:13 PM ETJul 11 dayDambkowski CarlChief Medical OfficerSSale−5.50K$132.74−$730.1K−3.0%177.9K after10b5-1
Jun 24, 2026 (view filing)Jun 222 daysDambkowski CarlChief Medical OfficerSSale−26.4K$132.60−$3.50M−12.8%179.2K after10b5-1
Jun 24, 2026 (view filing)Jun 222 daysHenderson Michael ThomasChief Executive OfficerSSale−80.0K$132.54−$10.6M−7.3%1.02M after10b5-1
Jun 12, 2026 (view filing)Jun 102 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$83.38−$1.67M−1.8%1.10M after6 lots10b5-1
Jun 5, 2026 (view filing)Jun 32 daysDambkowski CarlChief Medical OfficerSSale−5.50K$78.71−$432.9K−2.6%205.6K after10b5-1
May 15, 2026 (view filing)May 132 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$82.09−$1.64M−1.8%1.12M after2 lots10b5-1
May 8, 2026 (view filing)May 62 daysDambkowski CarlChief Medical OfficerSSale−5.50K$84.14−$462.8K−2.6%207.0K after2 lots10b5-1
May 4, 2026 (view filing)May 13 daysHenderson JaneChief Financial OfficerSSale−2.00K$82.04−$164.1K−1.1%173.4K after3 lots10b5-1
Apr 17, 2026 (view filing)Apr 161 dayHenderson JaneChief Financial OfficerSSale−2.00K$90.00−$180.0K−1.1%175.4K after10b5-1
Apr 10, 2026 (view filing)Apr 82 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$82.58−$1.65M−1.7%1.13M after3 lots10b5-1
Apr 3, 2026 (view filing)Apr 12 daysDambkowski CarlChief Medical OfficerSSale−5.50K$84.84−$466.6K−2.6%208.4K after3 lots10b5-1
Apr 3, 2026 (view filing)Apr 12 daysHenderson JaneChief Financial OfficerSSale−2.00K$85.01−$170.0K−1.1%177.4K after2 lots10b5-1
Mar 27, 2026 (view filing)Mar 252 daysHenderson JaneChief Financial OfficerSSale−2.00K$85.00−$170.0K−1.1%179.4K after10b5-1
Mar 13, 2026 (view filing)Mar 112 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$74.78−$1.50M−1.7%1.15M after3 lots10b5-1
Mar 6, 2026 (view filing)Mar 42 daysDambkowski CarlChief Medical OfficerSSale−5.50K$71.06−$390.8K−2.6%209.8K after3 lots10b5-1
Mar 4, 2026 (view filing)Mar 22 daysHenderson JaneChief Financial OfficerSSale−2.00K$70.22−$140.4K−1.1%181.4K after4 lots10b5-1
Feb 13, 2026 (view filing)Feb 112 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$63.35−$1.27M−1.7%1.17M after3 lots10b5-1
Feb 4, 2026 (view filing)Feb 4Same dayDambkowski CarlChief Medical OfficerSSale−5.50K$65.79−$361.9K−2.5%211.1K after5 lots10b5-1
Feb 4, 2026 (view filing)Feb 22 daysHenderson JaneChief Financial OfficerSSale−2.00K$65.81−$131.6K−1.1%183.4K after3 lots10b5-1
Jan 22, 2026 (view filing)8:07 PM ETJan 22Same dayHarwin Peter Evan and 3 othersDirectorSSale−1.75M$76.30−$133.5M−85.4%298.6K after
Jan 16, 2026 (view filing)Jan 142 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$81.11−$1.62M−1.6%1.19M after6 lots10b5-1
Jan 9, 2026 (view filing)Jan 72 daysDambkowski CarlChief Medical OfficerSSale−18.7K$77.84−$1.46M−8.1%212.5K after4 lots10b5-1
Jan 6, 2026 (view filing)Jan 2-64 daysHenderson JaneChief Financial OfficerSSale−8.00K$76.14−$609.1K−4.1%185.4K after3 lots10b5-1
Dec 23, 2025 (view filing)Dec 194 daysHenderson JaneChief Financial OfficerSSale−1.50K$80.00−$120.0K−0.8%193.4K after10b5-1
Dec 12, 2025 (view filing)Dec 102 daysHenderson Michael ThomasChief Executive OfficerSSale−20.0K$75.38−$1.51M−1.6%1.21M after3 lots10b5-1
Dec 5, 2025 (view filing)Dec 41 dayDambkowski CarlChief Medical OfficerSSale−10.9K$75.00−$817.5K−3.9%271.1K after10b5-1
Dec 5, 2025 (view filing)Dec 41 dayHenderson JaneChief Financial OfficerSSale−1.50K$75.00−$112.5K−0.8%194.9K after10b5-1
Dec 5, 2025 (view filing)Dec 41 dayHenderson Michael ThomasChief Executive OfficerSSale−40.0K$75.01−$3.00M−3.1%1.23M after10b5-1
Nov 28, 2025 (view filing)Nov 253 daysHenderson JaneChief Financial OfficerSSale−1.50K$70.00−$105.0K−0.8%196.4K after10b5-1
Nov 14, 2025 (view filing)Nov 14Same dayHenderson JaneChief Financial OfficerSSale−2.00K$65.00−$130.0K−1.0%197.9K after10b5-1
Nov 13, 2025 (view filing)Nov 112 daysHenderson JaneChief Financial OfficerSSale−1.00K$60.00−$60.0K−0.5%199.9K after10b5-1
Nov 13, 2025 (view filing)Nov 13Same dayHenderson Michael ThomasChief Executive OfficerSSale−20.0K$63.01−$1.26M−1.5%1.27M after4 lots10b5-1
Nov 7, 2025 (view filing)Nov 52 daysDambkowski CarlChief Medical OfficerSSale−10.8K$55.07−$593.9K−3.7%282.0K after4 lots10b5-1
Oct 15, 2025 (view filing)Oct 105 daysShah Nimish PDirectorPPurchase+365.9K$41.00+$15.0M–365.9K afterDerivative
Oct 3, 2025 (view filing)Oct 12 daysDambkowski CarlChief Medical OfficerSSale−5.11K$39.80−$203.4K−1.8%284.7K after10b5-1
Sep 5, 2025 (view filing)Sep 32 daysDambkowski CarlChief Medical OfficerSSale−2.73K$37.87−$103.2K−1.2%233.5K after2 lots10b5-1
Aug 8, 2025 (view filing)Aug 62 daysDambkowski CarlChief Medical OfficerSSale−2.73K$37.78−$103.0K−1.1%236.3K after10b5-1
Jul 3, 2025 (view filing)Jul 21 dayDambkowski CarlChief Medical OfficerSSale−10.1K$45.09−$455.0K−4.1%239.0K after3 lots10b5-1
Jun 6, 2025 (view filing)Jun 42 daysDambkowski CarlChief Medical OfficerSSale−2.73K$36.96−$100.7K−1.1%241.7K after10b5-1
May 9, 2025 (view filing)May 72 daysDambkowski CarlChief Medical OfficerSSale−2.73K$35.75−$97.4K−1.1%244.4K after10b5-1
Apr 4, 2025 (view filing)Apr 22 daysDambkowski CarlChief Medical OfficerSSale−3.86K$36.22−$139.8K−1.5%247.2K after3 lots10b5-1
Mar 7, 2025 (view filing)Mar 52 daysDambkowski CarlChief Medical OfficerSSale−1.59K$30.48−$48.5K−0.6%251.0K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysHenderson Michael ThomasChief Executive OfficerSSale−10.0K$30.15−$301.5K−0.8%1.29M after2 lots10b5-1
Feb 7, 2025 (view filing)Feb 52 daysDambkowski CarlChief Medical OfficerSSale−3.52K$40.69−$143.2K−1.4%252.6K after10b5-1
Feb 7, 2025 (view filing)Feb 52 daysHenderson Michael ThomasChief Executive OfficerSSale−15.0K$40.58−$608.7K−1.1%1.30M after10b5-1
Jan 10, 2025 (view filing)Jan 82 daysHenderson Michael ThomasChief Executive OfficerSSale−15.0K$48.85−$732.7K−1.1%1.31M after2 lots10b5-1
Jan 3, 2025 (view filing)Jan 21 dayDambkowski CarlChief Medical OfficerSSale−4.08K$46.94−$191.7K−1.6%255.3K after3 lots10b5-1
Dec 16, 2024 (view filing)Dec 124 daysMcKenna Mark C.DirectorPPurchase+20.0K$49.54+$990.8KNew position20.0K after2 lots